Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04696731 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | PHASE1 | ACTIVE NOT_RECRUITING | 120 | — | — | Feb 24, 2021 | Dec 1, 2025 | Sep 25, 2025 | 10 | United States |
| Arm | Type | Description |
|---|---|---|
| ALLO-647, ALLO-316 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALLO-316 | GENETIC | ALLO-316 is an allogeneic CAR T cell therapy targeting CD70 |
| ALLO-647 | BIOLOGICAL | ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: * Histologically confirmed renal cell carcinoma with a predominant clear cell component. * Must have received a checkpoint inhibitor and a VEGF inhibitor in the advanced and/or metastatic setting. * At least one measurable lesion as defined by RECIST version 1.1 * Eastern Cooper...